287 related articles for article (PubMed ID: 37920169)
1. Successes and challenges in modeling heterogeneous BRAF
Xing YL; Panovska D; Petritsch CK
Front Oncol; 2023; 13():1223199. PubMed ID: 37920169
[TBL] [Abstract][Full Text] [Related]
2. Frequency of BRAF V600E mutations in 969 central nervous system neoplasms.
Behling F; Barrantes-Freer A; Skardelly M; Nieser M; Christians A; Stockhammer F; Rohde V; Tatagiba M; Hartmann C; Stadelmann C; Schittenhelm J
Diagn Pathol; 2016 Jun; 11(1):55. PubMed ID: 27350555
[TBL] [Abstract][Full Text] [Related]
3. Response and resistance to BRAF
Capogiri M; De Micheli AJ; Lassaletta A; Muñoz DP; Coppé JP; Mueller S; Guerreiro Stucklin AS
Front Oncol; 2022; 12():1074726. PubMed ID: 36698391
[TBL] [Abstract][Full Text] [Related]
4. BRAF V600E mutation in Juvenile Xanthogranuloma family neoplasms of the central nervous system (CNS-JXG): a revised diagnostic algorithm to include pediatric Erdheim-Chester disease.
Picarsic J; Pysher T; Zhou H; Fluchel M; Pettit T; Whitehead M; Surrey LF; Harding B; Goldstein G; Fellig Y; Weintraub M; Mobley BC; Sharples PM; Sulis ML; Diamond EL; Jaffe R; Shekdar K; Santi M
Acta Neuropathol Commun; 2019 Nov; 7(1):168. PubMed ID: 31685033
[TBL] [Abstract][Full Text] [Related]
5. BRAFV600E Mutations in High-Grade Colorectal Neuroendocrine Tumors May Predict Responsiveness to BRAF-MEK Combination Therapy.
Klempner SJ; Gershenhorn B; Tran P; Lee TK; Erlander MG; Gowen K; Schrock AB; Morosini D; Ross JS; Miller VA; Stephens PJ; Ou SH; Ali SM
Cancer Discov; 2016 Jun; 6(6):594-600. PubMed ID: 27048246
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic and Prognostic Implications of BRAF V600E in Pediatric Low-Grade Gliomas.
Lassaletta A; Zapotocky M; Mistry M; Ramaswamy V; Honnorat M; Krishnatry R; Guerreiro Stucklin A; Zhukova N; Arnoldo A; Ryall S; Ling C; McKeown T; Loukides J; Cruz O; de Torres C; Ho CY; Packer RJ; Tatevossian R; Qaddoumi I; Harreld JH; Dalton JD; Mulcahy-Levy J; Foreman N; Karajannis MA; Wang S; Snuderl M; Nageswara Rao A; Giannini C; Kieran M; Ligon KL; Garre ML; Nozza P; Mascelli S; Raso A; Mueller S; Nicolaides T; Silva K; Perbet R; Vasiljevic A; Faure Conter C; Frappaz D; Leary S; Crane C; Chan A; Ng HK; Shi ZF; Mao Y; Finch E; Eisenstat D; Wilson B; Carret AS; Hauser P; Sumerauer D; Krskova L; Larouche V; Fleming A; Zelcer S; Jabado N; Rutka JT; Dirks P; Taylor MD; Chen S; Bartels U; Huang A; Ellison DW; Bouffet E; Hawkins C; Tabori U
J Clin Oncol; 2017 Sep; 35(25):2934-2941. PubMed ID: 28727518
[TBL] [Abstract][Full Text] [Related]
7. Development of Novel Murine BRAF
Branigan GP; Casado-Medrano V; O'Neill AB; Ricarte-Filho JC; Massoll N; Salwen M; Spangler Z; Scheerer M; Williamson EK; Bauer AJ; Franco AT
Cancers (Basel); 2023 Jan; 15(3):. PubMed ID: 36765847
[TBL] [Abstract][Full Text] [Related]
8. Implications of BRAF V600E mutation in gliomas: Molecular considerations, prognostic value and treatment evolution.
Di Nunno V; Gatto L; Tosoni A; Bartolini S; Franceschi E
Front Oncol; 2022; 12():1067252. PubMed ID: 36686797
[TBL] [Abstract][Full Text] [Related]
9. Xenotransplantation of pediatric low grade gliomas confirms the enrichment of
Kogiso M; Qi L; Lindsay H; Huang Y; Zhao X; Liu Z; Braun FK; Du Y; Zhang H; Bae G; Zhao S; Injac SG; Sobieski M; Brunell D; Mehta V; Tran D; Murray J; Baxter PA; Yuan XJ; Su JM; Adesina A; Perlaky L; Chintagumpala M; Parsons DW; Lau CC; Stephan CC; Lu X; Li XN
Oncotarget; 2017 Oct; 8(50):87455-87471. PubMed ID: 29152094
[TBL] [Abstract][Full Text] [Related]
10. Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma.
Schindler G; Capper D; Meyer J; Janzarik W; Omran H; Herold-Mende C; Schmieder K; Wesseling P; Mawrin C; Hasselblatt M; Louis DN; Korshunov A; Pfister S; Hartmann C; Paulus W; Reifenberger G; von Deimling A
Acta Neuropathol; 2011 Mar; 121(3):397-405. PubMed ID: 21274720
[TBL] [Abstract][Full Text] [Related]
11. Case report:
Cronin C; McLaughlin R; Lane L; Brett FM; Jansen M; Bermingham N; Wyse G; Grogan L; Morris PG; O'Reilly S
Front Med (Lausanne); 2022; 9():1070828. PubMed ID: 36619621
[No Abstract] [Full Text] [Related]
12. Dabrafenib plus trametinib in patients with BRAF
Subbiah V; Lassen U; Élez E; Italiano A; Curigliano G; Javle M; de Braud F; Prager GW; Greil R; Stein A; Fasolo A; Schellens JHM; Wen PY; Viele K; Boran AD; Gasal E; Burgess P; Ilankumaran P; Wainberg ZA
Lancet Oncol; 2020 Sep; 21(9):1234-1243. PubMed ID: 32818466
[TBL] [Abstract][Full Text] [Related]
13. BRAF V600E mutation and 9p21: CDKN2A/B and MTAP co-deletions - Markers in the clinical stratification of pediatric gliomas.
Frazão L; do Carmo Martins M; Nunes VM; Pimentel J; Faria C; Miguéns J; Sagarribay A; Matos M; Salgado D; Nunes S; Mafra M; Roque L
BMC Cancer; 2018 Dec; 18(1):1259. PubMed ID: 30558563
[TBL] [Abstract][Full Text] [Related]
14. BRAF mutation and CDKN2A deletion define a clinically distinct subgroup of childhood secondary high-grade glioma.
Mistry M; Zhukova N; Merico D; Rakopoulos P; Krishnatry R; Shago M; Stavropoulos J; Alon N; Pole JD; Ray PN; Navickiene V; Mangerel J; Remke M; Buczkowicz P; Ramaswamy V; Guerreiro Stucklin A; Li M; Young EJ; Zhang C; Castelo-Branco P; Bakry D; Laughlin S; Shlien A; Chan J; Ligon KL; Rutka JT; Dirks PB; Taylor MD; Greenberg M; Malkin D; Huang A; Bouffet E; Hawkins CE; Tabori U
J Clin Oncol; 2015 Mar; 33(9):1015-22. PubMed ID: 25667294
[TBL] [Abstract][Full Text] [Related]
15.
Del Bufalo F; Ceglie G; Cacchione A; Alessi I; Colafati GS; Carai A; Diomedi-Camassei F; De Billy E; Agolini E; Mastronuzzi A; Locatelli F
Front Oncol; 2018; 8():526. PubMed ID: 30488019
[TBL] [Abstract][Full Text] [Related]
16. Immunohistochemical testing of BRAF V600E status in 1,120 tumor tissue samples of patients with brain metastases.
Capper D; Berghoff AS; Magerle M; Ilhan A; Wöhrer A; Hackl M; Pichler J; Pusch S; Meyer J; Habel A; Petzelbauer P; Birner P; von Deimling A; Preusser M
Acta Neuropathol; 2012 Feb; 123(2):223-33. PubMed ID: 22012135
[TBL] [Abstract][Full Text] [Related]
17. Targeted therapy for BRAFV600E malignant astrocytoma.
Nicolaides TP; Li H; Solomon DA; Hariono S; Hashizume R; Barkovich K; Baker SJ; Paugh BS; Jones C; Forshew T; Hindley GF; Hodgson JG; Kim JS; Rowitch DH; Weiss WA; Waldman TA; James CD
Clin Cancer Res; 2011 Dec; 17(24):7595-604. PubMed ID: 22038996
[TBL] [Abstract][Full Text] [Related]
18. Clinicopathologic features and treatment efficacy of Chinese patients with BRAF-mutated metastatic colorectal cancer: a retrospective observational study.
Wang X; Wei Q; Gao J; Li J; Li J; Gong J; Li Y; Shen L
Chin J Cancer; 2017 Oct; 36(1):81. PubMed ID: 29037218
[TBL] [Abstract][Full Text] [Related]
19. The combination of novel targeted molecular agents and radiation in the treatment of pediatric gliomas.
Dasgupta T; Haas-Kogan DA
Front Oncol; 2013; 3():110. PubMed ID: 23717811
[TBL] [Abstract][Full Text] [Related]
20. Survival advantage combining a BRAF inhibitor and radiation in BRAF V600E-mutant glioma.
Dasgupta T; Olow AK; Yang X; Hashizume R; Nicolaides TP; Tom M; Aoki Y; Berger MS; Weiss WA; Stalpers LJ; Prados M; James CD; Mueller S; Haas-Kogan DA
J Neurooncol; 2016 Feb; 126(3):385-93. PubMed ID: 26384810
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
